

## **Reference Data**

### 2nd Quarter - Fiscal Year 2009 (April 1, 2009 to September 30, 2009)

#### Consolidated Earnings

- Consolidated Financial Data P 1
- Consolidated Balance Sheets P 2
- Consolidated P/L Statement P 3
- Consolidated Sales Breakdown by Category P 4
- Consolidated Operating Income by Category P 4
- Consolidated Sales -
  - Leading Brands of Self-Medication Operations P 5
- Consolidated Sales -
  - Leading Products of Prescription Pharmaceutical Operations P 6
- Major Subsidiaries : Trend of Sales and Earnings P 6
- Capital Expenditure P 7
- Depreciation Costs P 7
- R&D Expenses P 7
- Subsidiaries and Affiliates P 8
- <Reference> Three months sales data P 9
- <Reference> Shareholders Information P10

#### New Drug Development / New Products

- Prescription Pharmaceutical operations:
  - New Drug Development P11
- Launch of New Products P13

## Consolidated Financial Data

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E new	Full year E previous
Net Sales	61,853	126,314	199,797	256,213	63,563	129,755	262,000	257,000
(YOY%)	(+8.7%)	(+4.6%)	(+3.3%)	(+2.6%)	(+2.8%)	(+2.7%)	(+2.3%)	(+0.3%)
Self-Medication operations	38,649	82,511	127,392	161,141	38,563	81,636	161,900	162,500
Prescription Pharmaceutical operations	23,203	43,803	72,405	95,072	24,999	48,118	100,100	94,500
Gross profit	42,092	84,992	133,291	169,462	41,465	84,497	170,200	168,500
Selling, general and administrative expenses	30,447	65,509	100,811	131,526	35,209	66,298	135,700	134,500
Research and development expenses	5,758	15,038	21,437	27,523	9,209	14,440	28,400	28,700
(% Sales)	(9.3%)	(11.9%)	(10.7%)	(10.7%)	(14.5%)	(11.1%)	(10.8%)	(11.2%)
Advertising expenses	3,507	7,205	13,180	16,531	4,472	8,434	17,300	17,300
Sales promotion expenses	5,163	10,906	17,656	23,372	5,805	11,875	25,400	24,600
Personnel expenses	8,382	16,640	24,902	32,947	8,508	16,844	33,800	33,700
Operating income	11,644	19,483	32,479	37,935	6,256	18,199	34,500	34,000
(YOY%)	(+42.5%)	(+1.9%)	(-1.2%)	(+2.7%)	(-46.3%)	(-6.6%)	(-9.1%)	(-10.4%)
Ordinary income	12,360	20,757	34,149	39,902	7,074	18,855	36,000	39,000
(YOY%)	(+26.5%)	(-7.5%)	(-8.6%)	(-4.8%)	(-42.8%)	(-9.2%)	(-9.8%)	(-2.3%)
Net income	7,693	-1,053	4,695	8,815	3,580	10,364	19,500	23,000
(YOY%)	(+27.9%)	( - )	(-79.7%)	(-64.7%)	(-53.5%)	( - )	(+121.2%)	(+160.9%)
EPS (yen)	25.87	-3.56	15.94	30.01	12.48	36.14	67.99	80.19
BPS (yen)	1,830.90	1,778.72	1,754.96	1,745.96	1,769.73	1,790.16	1,808.63	1,812.93
Dividend per share(yen)	-	12.00	-	27.00	-	12.00	27.00	27.00
Payout Ratio	-	-	-	90.0%	-	-	39.7%	33.7%
Capital expenditure	367	1,859	3,789	5,814	1,185	3,967	8,600	7,400
Depreciation and amortization	2,625	5,313	8,096	11,014	2,557	5,223	11,600	10,900
Total assets	625,663	600,679	600,604	591,568	593,411	600,565	606,000	607,000
Shareholders' equity	552,953	528,605	522,007	514,511	517,203	523,341	529,000	530,000
Return on equity(%) *	-	-	-	1.7%	-	-	3.8%	4.5%
Return on assets(%) *	-	-	-	1.4%	-	-	3.3%	3.8%
Equity ratio(%)	87.0%	86.5%	85.4%	85.4%	85.5%	85.5%	85.6%	85.7%
Overseas sales	2,776	4,913	6,717	8,184	1,637	3,429	-	-
(% Sales)	4.5%	3.9%	3.4%	3.2%	2.6%	2.6%	-	-
Number of employees	5,504	5,491	5,456	5,409	5,524	5,529	-	-

E=Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

\* Average of the beginning and year-end balance of shareholders' equity / total assets

## Consolidated Balance Sheets

(Millions of yen)

	End of FY2008		End of 2Q 2009		Change	
	(March 31, 09)	% total	(Sept. 31, 09)	% total		
<b>(Assets)</b>						
<b>I Current assets:</b>	215,872	36.5%	217,355	36.2%	+1,482	
Cash and deposits	112,989		116,142		+3,152	
Notes and accounts receivable-trade	61,968		64,392		+2,423	
Marketable securities	2,918		3,092		+173	Transferred from investment securities: +1,000, Bond redemption: -910
Inventories	22,146		23,249		+1,103	Merchandise and finished goods: -214, work in progress: +280, raw materials and supplies: +1,037
Deferred tax assets	7,450		7,103		-346	
Others	8,398		3,375		-5,023	Money trust for repurchase of treasury shares: -4,713
<b>II Fixed assets:</b>	375,696	63.5%	383,209	63.8%	+7,513	
<b>(1) Tangible fixed assets:</b>	92,961	(15.7%)	92,715	(15.5%)	-245	
Buildings and structures	48,681		47,684		-996	Buildings: -886, structures: -110
Machinery and equipment	9,211		9,342		+130	Machinery: +118, vehicles: +11
Land	29,652		30,820		+1,168	Acquisition of business-use land
Others	5,415		4,867		-548	
<b>(2) Intangible fixed assets:</b>	10,108	(1.7%)	9,207	(1.5%)	-900	
Goodwill	2,484		2,418		-65	
Trademarks	2,443		2,067		-376	Vicks trademark amortization
Software	4,978		4,529		-448	
Others	202		191		-10	
<b>(3) Investments and other assets:</b>	272,626	(46.1%)	281,286	(46.8%)	+8,660	
Investments in securities	205,410		218,629		+13,219	Bond acquisition: +35,000, Bond redemption: -30,000, Increase in evaluation gain: +9,351, Transferred to marketable securities -1,000
Affiliates' stock	46,706		44,804		-1,901	
Deferred tax assets	14,121		11,344		-2,776	Decrease due to increase in evaluation gain of investments in securities
Others	6,388		6,507		+118	
<b>Total assets</b>	<b>591,568</b>	<b>100.0%</b>	<b>600,565</b>	<b>100.0%</b>	<b>+8,996</b>	

<b>(Liabilities)</b>						
<b>I Current liabilities:</b>	54,130	9.1%	54,807	9.1%	+677	
Notes and accounts payable-trade	20,149		22,459		+2,309	
Accounts payable	11,265		9,846		-1,419	
Accrued corporate tax	9,193		8,172		-1,020	
Allowance for bonuses	4,326		4,384		+57	
Others	9,194		9,943		+749	
<b>II Long-term liabilities:</b>	22,927	3.9%	22,416	3.8%	-510	
Reserves for retirement benefits	15,937		16,400		+463	
Deferred taxes liabilities	424		471		+46	
Others	6,565		5,545		-1,020	
<b>Total liabilities</b>	<b>77,057</b>	<b>13.0%</b>	<b>77,224</b>	<b>12.9%</b>	<b>+166</b>	
<b>(Net assets)</b>						
<b>I Shareholders' equity</b>	516,948	87.4%	518,197	86.3%	+1,248	
Common Stock	29,804	5.0%	29,804	5.0%	-	
Additional paid-in capital	14,935	2.5%	14,935	2.5%	-	
Retained earnings	535,393	90.5%	501,049	83.4%	-34,343	Net income: +10,364, Payment of dividend: -4,343 Cancellation of treasury stock -40,365
Treasury stock	-63,183	-10.6%	-27,591	-4.6%	+35,592	Acquisition of treasury stock -4,772, Cancellation +40,365
<b>II Valuation, translation, adjustments and</b>	-11,782	-2.0%	-4,776	-0.8%	+7,006	
Unrealized gain on securities	-3,752	-0.6%	1,931	0.3%	+5,683	Increase in evaluation gain of investments in securities
Others	-8,030	-1.4%	-6,707	-1.1%	+1,322	Increase of foreign currency adjustment accounts
<b>III Minority interest</b>	9,344	1.6%	9,919	1.6%	+574	
<b>Total net assets</b>	<b>514,511</b>	<b>87.0%</b>	<b>523,341</b>	<b>87.1%</b>	<b>+8,829</b>	
<b>Total liabilities and net assets</b>	<b>591,568</b>	<b>100.0%</b>	<b>600,565</b>	<b>100.0%</b>	<b>+8,996</b>	

## Consolidated P/L Statement

(Millions of yen)

	FY2008 2Q (April-Sept.)		FY2009 2Q (April-Sept.)		YOY Change	Explanatory comments
		% Sales		% Sales		
Net sales	126,314	100.0%	129,755	100.0%	+3,441	
Cost of sales	41,437	32.8%	45,228	34.9%	+3,790	
Gross profit on sales	84,876	67.2%	84,527	65.1%	-349	
Provision for sales returns	-115		29		+145	
Gross profit	84,992	67.3%	84,497	65.1%	-494	
Selling, general and administrative expenses	65,509	51.9%	66,298	51.1%	+789	
Research and development expenses	15,038		14,440		-598	
Advertising expenses	7,205		8,434		+1,228	Increase for advertising costs for new products
Sales promotion expenses	10,906		11,875		+969	Increase for sales promotion costs for new products Increase due to response to revision of OTC
Personnel expenses	16,640		16,844		+204	Increase for retirement benefit expenses
Others	15,717		14,703		-1,014	Decrease for amortization of goodwill, etc.
Operating income	19,483	15.4%	18,199	14.0%	-1,284	
Non-operating income	3,352	2.7%	3,180	2.4%	-172	
Non-operating expenses	2,079	1.7%	2,523	1.9%	+443	
Ordinary income	20,757	16.4%	18,855	14.5%	-1,901	
Extraordinary gains	975	0.8%	4	0.0%	-971	Loss of 891 on prior-period adjustment for same period of previous year
Extraordinary losses	13,394	10.6%	48	0.0%	-13,346	For same period of previous year, losses of 12,852 on temporary amortization of goodwill and of 502 on loss on devaluation of investment securities
Income before income taxes and minority interests	8,338	6.6%	18,811	14.5%	+10,473	
Income taxes	9,030	7.1%	7,707	5.9%	-1,322	
Minority interest gain (loss) of consolidated subsidiaries	361	0.3%	739	0.6%	+377	
Net income	-1,053	-0.8%	10,364	8.0%	+11,418	

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated Sales Breakdown by Category

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E new	Full year E previous
Self-Medication operations (YOY%)	38,649 (+11.5%)	82,511 (+9.5%)	127,392 (+7.5%)	161,141 (+5.5%)	38,563 (-0.2%)	81,636 (-1.1%)	161,900 (+0.5%)	162,500 (+0.8%)
OTC products, etc.	35,616	75,990	117,316	148,229	35,184	74,417	148,100	149,400
Foods for Specified Health Use, etc.	2,366	5,004	7,727	9,921	2,415	5,243	9,800	9,500
Others	667	1,517	2,349	2,991	964	1,976	4,000	3,600
Prescription Pharmaceutical operations (YOY%)	23,203 (+4.4%)	43,803 (-3.5%)	72,405 (-3.4%)	95,072 (-2.0%)	24,999 (+7.7%)	48,118 (+9.9%)	100,100 (+5.3%)	94,500 (-0.6%)
Ethical drugs	19,943	38,337	64,646	84,712	22,851	43,804	90,200	85,000
Others	2,083	4,180	6,400	8,748	2,012	4,133	9,400	8,900
Royalty income	1,177	1,286	1,359	1,612	136	181	500	600
<b>Total</b>	<b>61,853</b>	<b>126,314</b>	<b>199,797</b>	<b>256,213</b>	<b>63,563</b>	<b>129,755</b>	<b>262,000</b>	<b>257,000</b>

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated Operating Income by Category

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E new	Full year E previous
Self-Medication operations (YOY%)	8,863 (+70.5%)	18,663 (+33.0%)	25,631 (+10.6%)	29,227 (+11.7%)	6,516 (-26.5%)	16,098 (-13.7%)	29,700 (+1.6%)	31,000 (+6.1%)
Prescription Pharmaceutical operations (YOY%)	2,781 (-6.6%)	820 (-83.9%)	6,847 (-29.4%)	8,707 (-19.2%)	-259 (-)	2,100 (+156.1%)	4,800 (-44.9%)	3,000 (-65.5%)
<b>Total</b>	<b>11,644</b>	<b>19,483</b>	<b>32,479</b>	<b>37,935</b>	<b>6,256</b>	<b>18,199</b>	<b>34,500</b>	<b>34,000</b>

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E new	Full year E previous
Lipovitan series	19.7	42.4	61.5	74.8	18.5	39.9	-6.0%	71.9	72.9
Lipovitan D	14.4	30.4	43.6	52.8	13.3	28.1	-7.6%	49.7	50.5
Others	5.4	12.0	17.9	22.0	5.3	11.8	-1.8%	22.2	22.4
(100mL other Lipovitans)	3.3	7.3	10.8	13.3	3.3	7.3	+0.5%	13.5	14.0
(50mL other Lipovitans)	2.1	4.7	7.0	8.7	2.0	4.4	-5.4%	8.7	8.4
Pabron series	4.3	9.4	18.2	25.4	4.7	10.6	+12.9%	26.6	26.3
RiUP series	2.8	5.8	9.0	11.4	3.3	6.4	+10.2%	12.7	13.0
Gastrointestinal treatment series	1.0	2.1	3.5	4.4	1.0	2.1	-1.3%	4.3	4.5
ZENA series	1.0	1.9	3.0	3.9	0.9	1.7	-9.4%	3.5	3.7
Naron Series	1.0	2.1	3.3	4.4	1.1	2.3	+6.0%	4.6	4.7
Colac Series	0.9	1.9	3.0	3.9	1.0	1.9	+2.6%	4.0	4.0
VICKS series	0.4	0.9	2.3	2.9	0.4	1.1	+23.8%	3.2	3.0
Livita series	0.7	1.3	2.0	2.6	0.7	1.4	+11.9%	3.0	2.9
Overseas drinks	1.4	3.1	4.7	6.0	1.3	2.8	-10.0%	5.4	5.5

(Rounded to the nearest hundred-million)

E=Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

### Energy Drinks: Domestic Sales Breakdown by Channel (parent basis)

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY
Drug-oriented channels	10.6	22.6	32.8	39.9	10.0	20.7	-8.6%
Food-oriented channels	10.3	22.4	32.7	40.0	9.8	21.7	-3.0%
Total	20.9	45.0	65.5	79.9	19.7	42.4	-5.8%

(Rounded to the nearest hundred-million)

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

### Lipovitan D: Domestic Sales Breakdown by Channel (parent basis)

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY
Drug-oriented channels	6.7	14.0	19.9	23.7	6.1	12.2	-12.4%
Food-oriented channels	7.7	16.4	23.8	29.1	7.2	15.9	-3.5%
Total	14.4	30.4	43.6	52.8	13.3	28.1	-7.6%

(Rounded to the nearest hundred-million)

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E new	Full year E previous
Clarith	5.7	9.8	17.4	24.0	5.4	10.1	+2.4%	24	24
Palux	2.9	5.6	8.7	11.2	2.8	5.5	-1.1%	11	11
Zosyn*	0.4	0.9	2.4	4.0	2.5	5.1	+494.3%	10	8
Geninax	0.1	1.0	3.3	3.7	1.6	2.7	+172.0%	5	5
PENTCILLIN	1.5	2.9	4.5	5.5	1.2	2.3	-19.3%	4	4
Lorcam	1.1	2.1	3.1	4.0	1.0	2.0	-5.6%	4	4
TOMIRON	0.7	1.3	2.3	3.0	0.7	1.2	-7.5%	3	3
OZEX	0.7	1.3	2.2	3.0	0.6	1.2	-11.5%	3	3
LUPRAC	0.6	1.1	1.6	2.1	0.5	1.1	+1.0%	2	2
Metligine	0.5	1.0	1.5	1.9	0.5	1.0	-1.9%	2	2

(Rounded to the nearest hundred-million)

\* Figures for March 2009 were including sales of Tazocin

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Major Subsidiaries: Trend of Sales and Earnings

### Sales and Earnings of Taisho Toyama Pharmaceutical

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E new	Full year E previous
Net Sales	19.2	36.9	62.4	81.7	22.0	42.2	+14.6%	87.0	82.0
Taisho products	14.5	27.9	47.0	61.3	15.7	29.9	+7.4%	62.8	60.3
Toyama Chemical products	4.7	9.0	15.3	20.5	6.3	12.3	+36.8%	24.2	21.7
Operating income	0.1	0.5	3.3	3.7	1.5	2.6	+386.4%	3.4	2.0
Ordinary income	0.1	0.5	3.3	3.7	1.5	2.6	+378.4%	3.4	2.0
Net income	-0.1	0.1	1.6	1.7	0.8	1.3	-	1.5	0.7

(Rounded to the nearest hundred-million)

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

### Sales and Earnings of Biofermin Pharmaceutical

(Billions of yen)

	March 2009(FY2008)				March 2010 (FY2009)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E previous
Net Sales	2.2	4.4	6.6	8.5	2.1	4.4	-1.4%	8.4
Self medication	1.4	2.9	4.3	5.5	1.3	2.8	-5.0%	5.2
RX Pharmaceutical	0.8	1.5	2.4	3.1	0.8	1.6	+5.7%	3.2
Operating income	0.5	1.1	1.7	2.1	0.7	1.3	+12.8%	1.8
Ordinary income	0.6	1.2	1.8	2.2	0.7	1.3	+11.2%	1.9
Net income	0.3	0.7	1.1	1.4	0.4	0.8	+4.1%	1.1

(Rounded to the nearest hundred-million)

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated: Capital Expenditure

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E new	Full year E previous
Total capital expenditure	367	1,859	3,789	5,814	1,185	3,967	8,600	7,400
Taisho Pharmaceutical	245	1,469	2,865	4,687	472	2,886	6,900	5,700
Omiya Factory	82	472	735	1,404	79	770	2,300	2,300
Hanyu Factory	25	111	120	131	0	2	100	100
Okayama Factory	1	1	10	58	6	15	200	200
Research Center	14	203	469	801	19	190	1,100	1,100
Others	122	681	1,531	2,293	367	1,908	3,200	2,000
Subsidiaries	121	390	924	1,126	713	1,081	1,700	1,700

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

<Main capital expenditure>

- Non-consolidated

Acquisition of business-use land: ¥1,169 million

- Subsidiaries

Biofermin: ¥658 million

## Consolidated: Capital Expenditure

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E new	Full year E previous
Depreciation and amortization	2,625	5,313	8,096	11,014	2,557	5,223	11,600	10,900
Cost of sales	1,159	2,329	3,491	4,742	1,050	2,150	4,400	4,400
SGA expenses	1,465	2,984	4,605	6,272	1,507	3,073	7,200	6,500

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Consolidated: R&D Expenses

(Millions of yen)

	March 2009(FY2008)				March 2010 (FY2009)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E new	Full year E previous
Total R&D expenses	5,758	15,038	21,437	27,523	9,209	14,440	28,400	28,700
Self-Medication operations	1,241	3,024	5,753	7,222	1,741	3,032	6,000	6,300
Prescription Pharmaceutical	4,517	12,014	15,685	20,300	7,467	11,407	22,400	22,400

E = Estimates

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

## Subsidiaries and Affiliates

(As of September 30, 2009)

Company	Address	Capital	Business	Ownership *
(1) Consolidated subsidiaries				%
Taisho Kosei Service Co.,Ltd.	Tokyo, Japan	,000 Yen 10,000	SMG	100
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	56
Taisho Toyama Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 2,000,000	PD	70
Medwell Taisho Co.,Ltd.	Saitama, Japan	,000 Yen 200,000	PD	100
Mejiro Real Estate Co.,Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100
Shimoda Central Co.,Ltd.	Tokyo, Japan	,000 Yen 300,000	SMG	100
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100
Taisho Pharmaceutical (M) SDN. BHD.	Malaysia	,000 M\$ 24,380	SMG	100
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100
PT. Taisho Indonesia	Indonesia	,000 rupiah 42,920,000	SMG	100
Taisho Foods Deutschland GmbH	Germany	,000 Euro 306	SMG	100
Taisho Co.,Ltd. Shanghai	China	,000 CNY 132,621	SMG	100
Taisho Pharmaceutical Asia (M) SDN. BHD.	Malaysia	,000 M\$ 26,500	SMG	100
Taisho Pharmaceutical (Europe) Ltd.	United Kingdom	,000 £ 20,000	SMG	100
Taisho Vietnam Co.,Ltd.	Vietnam	,000 VND 170,754,300	SMG	100
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 163,000	SMG	100
Osotspa Taisho Co.,Ltd.	Thailand	,000 THB 15,000	SMG	49
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100
(2) Equity Accounting Method				
Toyama Chemical Co.,Ltd.	Tokyo, Japan	,000 Yen 37,400,593	PD	34
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	21
Taisho Hizon Manufacturing Inc.	Philippines	,000 Peso 17,000	SMG	50

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations  
\* including indirect ownership

<Reference> Sales Data for 1st and 2nd quarter (Three months)

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of yen)

	March 2009(FY2008)		March 2010 (FY2009)				Full year E new
	1Q (4-6)	2Q (7-9)	1Q (4-6)	YOY	2Q (7-9)	YOY	
Lipovitan series	19.7	22.7	18.5	-6.0%	21.3	-6.0%	71.9
Lipovitan D	14.4	16.0	13.3	-7.9%	14.9	-7.4%	49.7
Others	5.4	6.7	5.3	-1.0%	6.5	-2.5%	22.2
(100mL other Lipovitans)	3.3	4.0	3.3	+1.6%	4.0	-0.5%	13.5
(50mL other Lipovitans)	2.1	2.6	2.0	-5.1%	2.5	-5.6%	8.7
Pabron series	4.3	5.1	4.7	+8.3%	5.9	+16.8%	26.6
RiUP series	2.8	3.0	3.3	+18.7%	3.1	+2.3%	12.7
Gastrointestinal treatment series	1.0	1.1	1.0	+2.4%	1.1	-4.5%	4.3
ZENA series	1.0	0.9	0.9	-11.2%	0.9	-7.4%	3.5
Naron Series	1.0	1.1	1.1	+9.3%	1.2	+3.1%	4.6
Colac Series	0.9	1.0	1.0	+5.1%	1.0	+0.2%	4.0
VICKS series	0.4	0.5	0.4	+1.4%	0.7	+39.4%	3.2
Livita series	0.7	0.6	0.7	-2.8%	0.7	+30.0%	3.0
Overseas drinks	1.4	1.8	1.3	-3.6%	1.5	-15.0%	5.4

(Rounded to the nearest hundred-million)

E=Estimates

Energy Drinks: Domestic Sales Breakdown by Channel (parent basis)

(Billions of yen)

	March 2009(FY2008)		March 2010 (FY2009)			
	1Q (4-6)	2Q (7-9)	1Q (4-6)	YOY	2Q (7-9)	YOY
Drug-oriented channels	10.6	12.0	10.0	-6.2%	10.7	-10.6%
Food-oriented channels	10.3	12.1	9.8	-5.2%	11.9	-1.2%
Total	20.9	24.1	19.7	-5.7%	22.6	-5.9%

(Rounded to the nearest hundred-million)

Lipovitan D: Domestic Sales Breakdown by Channel (parent basis)

(Billions of yen)

	March 2009(FY2008)		March 2010 (FY2009)			
	1Q (4-6)	2Q (7-9)	1Q (4-6)	YOY	2Q (7-9)	YOY
Drug-oriented channels	6.7	7.3	6.1	-9.4%	6.2	-15.2%
Food-oriented channels	7.7	8.8	7.2	-6.5%	8.7	-1.0%
Total	14.4	16.0	13.3	-7.9%	14.9	-7.4%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of yen)

	March 2009(FY2008)		March 2010 (FY2009)				Full year E new
	1Q (4-6)	2Q (7-9)	1Q (4-6)	YOY	2Q (7-9)	YOY	
Clarith	5.7	4.1	5.4	-4.3%	4.6	+11.7%	24.4
Palux	2.9	2.7	2.8	-0.7%	2.7	-1.6%	11.0
Zosyn*	0.4	0.5	2.5	+580.2%	2.6	+428.4%	10.2
Geninax	0.1	0.9	1.6	-	1.2	+28.7%	5.4
PENTCILLIN	1.5	1.4	1.2	-19.9%	1.1	-18.6%	4.4
Lorcam	1.1	1.0	1.0	-4.1%	0.9	-7.2%	3.8
TOMIRON	0.7	0.6	0.7	-10.7%	0.6	-3.4%	2.6
OZEX	0.7	0.6	0.6	-12.9%	0.5	-9.6%	2.6
LUPRAC	0.6	0.5	0.5	-1.1%	0.5	+3.4%	2.1
Metligine	0.5	0.5	0.5	-5.3%	0.5	+1.6%	1.9

(Rounded to the nearest hundred-million) \* Figures for March 2009 were including sales of Tazocin

E=Estimates

## Shareholders Information (as of end of September 2009)

### Major Shareholders

(Thousands of Shares)

Shareholders	Number of shares	% of total
Uehara Memorial Foundation	43,000	14.98%
Shoji Uehara	36,614	12.76%
Taisho Pharmaceutical	13,461	-
Sumitomo Mitsui Banking Corp.	10,000	3.48%
The Bank of Tokyo-Mitsubishi UFJ	10,000	3.48%
Uehara Museum of Modern Art Foundation	10,000	3.48%
Akira Uehara	7,145	2.49%
Sumitomo Chemical	7,033	2.45%
Japan Trustee Services Bank, Ltd. (Trust account)	6,797	2.37%
Kajima Corporation	5,500	1.92%

Note(1): Number of shares are rounded down to the nearest 1,000.

% of total calculated excluding treasury stocks (13,461 thousand shares)

### Distribution of Shareholders

Financial Institutions	20.63%
Financial Instruments Firm	0.38%
Other companies	36.69%
Foreign Companies	11.29%
Individuals and Others	31.02%

% of total calculated excluding treasury stocks (13,461 thousand shares)

# Prescription Pharmaceutical operations: New Drug Development

As of October 30, 2009

## (1) Development in Japan

Filed for application

### 1) Clarith tab. 200

- < Application > Eradication by concomitant therapy (\*1) of *H. pylori* in gastric MALT lymphoma, the stomach after endoscopic resection of early stage gastric cancer, and idiopathic thrombocytopenic purpura
- < Description > Macrolide antibiotic
- < Remarks > Additional indication  
Joint application with 9 companies (\*2)  
\*1 Consists of a proton pump inhibitor (lansoprazole, omeprazole, and rabeprazole sodium), amoxicillin hydrate, and clarithromycin  
\*2 Taisho, ABBOTT JAPAN, Astellas, AstraZeneca, Eisai, Kyowa Hakko Kirin, Shionogi, Takeda, Mitsubishi Tanabe

### 2) CT-081

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Activated vitamin D<sub>3</sub> derivative
- < Remarks > Applied by Chugai Pharmaceutical  
Chugai Pharmaceutical development code: ED-71

Phase 2/3

### 1) CT-064 (Injection)

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Antiresorptive bisphosphonate
- < Remarks > Chugai Pharmaceutical development code: R484

Phase 2

### 1) TT-063

- < Application > Osteoarthritis, scapulohumeral periarthritis, myalgia and other conditions
- < Development > Co-development with Tokuhon
- < Description > Anti-inflammatory analgesic patch formulation containing S-flurbiprofen

### 2) NT-702

- < Application > Asthma
- < Development > Co-development with Nissan Chemical
- < Description > Expressed bronchodilatation and inhibition of cellular infiltration

### 3) NT-702

- < Application > Intermittent claudication caused by arteriosclerosis obliterans
- < Development > Co-development with Nissan Chemical
- < Description > Expressed vasodilation as well as platelet aggregate inhibition

# Prescription Pharmaceutical operations: New Drug Development

As of October 30, 2009

## (1) Development in Japan (continued)

Phase 2

### 4) CT-064 (Oral)

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Antiresorptive bisphosphonate
- < Remarks > Chugai Pharmaceutical development code: R484

### 5) TS-071

- < Application > Type 1 and 2 diabetes
- < Development > In-house
- < Description > Sodium-dependent glucose cotransporter (SGLT) inhibitor

### 6) TS-022

- < Application > Pruritus caused by atopic dermatitis
- < Development > In-house
- < Description > Prostaglandin derivative
- < Remarks > Overseas: Phase 2

### 7) Palux

- < Application > Intermittent claudication caused by spinal canal stenosis
- < Development > In-house
- < Description > Prostaglandin E1 preparation
- < Remarks > Additional indication

## (2) Development in Overseas Countries

Phase 2

### 1) TS-022

- < Application > Pruritus caused by atopic dermatitis
- < Development > In-house
- < Description > Prostaglandin derivative
- < Remarks > In Japan: Phase 2

# Launch of New Products

As of October 30, 2009

Self-Medication operations
----------------------------

## 1) IRIS CL

< Description > Relaunch of tear-like eye drops packaged in a special preservative-free container, a first for an OTC drug

< Launch > February 2009

---

## 2) Meditreat Cream

< Description > The first OTC cream-type treatment for recurrent vaginal candida formulated with miconazole nitrate

< Launch > March 2009

---

## 3) NARON ACE R

< Description > An antipyretic and analgesic formulated with five active ingredients, centered on the two fever and pain inhibitors ibuprofen and ethenzamide

< Launch > March 2009

---

## 4) Stopan

< Description > A switch-OTC analgesic gastrointestinal treatment formulated with the tiquizium bromide, a prescription-based anticholinergic agent

< Launch > April 2009

---

## 5) Diclotect (Tape, Gel and Lotion)

< Description > A switch-OTC topical analgesic and anti-inflammatory drug formulated with the prescription ingredient diclofenac sodium

< Launch > April 2009

---

## 6) Lipovitan Half

< Description > A 100 mL energy drink containing half the calories of *Lipovitan D*

< Launch > May 2009

---

## 7) RiUP X5

< Description > Pharmaceutical hair regrowth treatment for men formulated with 5% of the active hair regrowth ingredient minoxidil (5 times the amount contained in conventional *RiUP* products)

< Launch > June 2009

---

## 8) Flavan-age

< Description > A supplement sold exclusively by mail order that contains a water-soluble and fat-soluble antioxidative constituent

< Launch > June 2009

---

## Launch of New Products

As of October 30, 2009

Self-Medication operations (continued)
--

### 9) Lipovitan Ace

<Description> An energy drink containing 11 ingredients  
< Launch > August 2009

---

### 10) Anserine Powdered Green Tea

<Description> A powdered green tea formulated with anserine, a functional food material currently in the limelight  
< Launch > September 2009

---

### 11) Pabron Mask 365

<Description> A Japanese-made mask manufactured under the same quality controls as hospital-use surgical masks  
< Launch > September 2009

---

### 12) Lipovitan Gold Ace

<Description> An energy mini-drink containing 4 herbal ingredients  
< Launch > October 2009

---